What does this video actually claim?
@a_simonee96 says she's switching from one injection site to her thigh to break through a weight loss plateau on her GLP-1 medication. The implication is that changing injection sites might restart weight loss when it stalls.
She's asking her audience about their experiences with thigh injections specifically. The creator seems to believe that different injection sites might affect how well the medication works for weight loss.
Does injection site location affect GLP-1 effectiveness?
No credible evidence shows that switching injection sites breaks weight loss plateaus with GLP-1 medications. The STEP 1 trial (Wilding et al., NEJM, 2021) and other major semaglutide studies don't mention injection site rotation as a factor in maintaining weight loss.
GLP-1 medications like semaglutide work systemically once absorbed. Whether you inject in your abdomen, thigh, or upper arm, the drug enters your bloodstream and reaches the same receptors.
The FDA-approved prescribing information for Wegovy recommends rotating injection sites to prevent lipodystrophy (fat tissue changes), not to improve efficacy. Novo Nordisk's clinical trials used multiple injection sites without suggesting any affected weight loss outcomes.
What actually causes weight loss plateaus?
Weight loss plateaus on GLP-1 medications happen for well-documented reasons that have nothing to do with where you inject. The STEP 1 trial showed most weight loss occurred in the first 20 weeks, with gradual slowing afterward.
Your body adapts to lower calorie intake by reducing metabolic rate. The STEP 4 trial (Rubino et al., JAMA, 2021) found that people who stopped semaglutide regained 11.6% of their body weight within 68 weeks.
Some people also develop tolerance or need dose adjustments. The maximum approved dose is 2.4mg weekly for Wegovy, and if you're already there, changing injection sites won't create additional weight loss.
What should you know about injection site rotation?
You should rotate injection sites, but for medical safety, not weight loss enhancement. Using the same spot repeatedly can cause lipodystrophy, where fat tissue either builds up or disappears under the skin.
The prescribing information recommends spacing injections at least one inch apart from your previous injection. Abdomen, thigh, and upper arm are all approved sites with similar absorption rates.
If you're experiencing a plateau, talk to your healthcare provider about dose adjustments or realistic expectations. The STEP 1 trial showed 14.9% average weight loss, but individual results varied from minimal loss to over 20% reduction.